Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combined mirabegron and vaginal estrogen therapy in overactive bladder
IRCT20230629058615N14Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of mirabegron and DehydraTECH-estrogen in overactive bladder (OAB), sponsored by Iran University of Medical Sciences. Started Mar 2026; status: completed.
02
Drugs
mirabegronDehydraTECH-estrogen
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on IRCT20230629058615N14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230629058615N14.